Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 2 1Phase 1/2 1Phase 1 1

Status

Active not recruiting 2Recruiting 1Completed 1

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 4

Sponsor

Cancer Type

CNS 4

Conditions

Glioblastoma 3Meningeal Carcinomatosis 1Glioma 1

Interventions

Specimen Handling 662pembrolizumab 612Magnetic Resonance Spectroscopy 565Carboplatin 451Cisplatin 400Cyclophosphamide 399Biopsy 385Nivolumab 329Paclitaxel 324Gemcitabine 317Radiotherapy 302Bevacizumab 250Dexamethasone 223fludarabine 217Docetaxel 203durvalumab 196Oxaliplatin 189venetoclax 188atezolizumab 188Fluorouracil 178Rituximab 177Pemetrexed 174Capecitabine 172Radiation 171Doxorubicin 168Radiosurgery 161Ipilimumab 149Etoposide 142Leucovorin 141Lenalidomide 140

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
azeliragon × 90 days × Clear all
NCT05635734 2026-05-29

Azeliragon and Chemoradiotherapy in Newly Diagnosed Glioblastoma

Cantex Pharmaceuticals

Phase 1/2 Completed
33 enrolled
CNS

Glioblastoma

NCT06831526 2026-05-29

Neoadjuvant Chemoradiotherapy With or Without Concurrent Azeliragon in Patients With Newly Diagnosed Glioblastoma

Washington University School of Medicine

Phase EARLY_PHASE1 Recruiting
12 enrolled
CNS

Glioblastoma

NCT06724926 2026-05-18

Concurrent Azeliragon With Craniospinal Irradiation

NYU Langone Health

Phase 1 Active not recruiting
21 enrolled
CNS

Glioma, Meningeal Carcinomatosis

NCT05986851 2026-03-31

Azeliragon in MGMT Unmethylated Glioblastoma

Cantex Pharmaceuticals

Phase 2 Active not recruiting
30 enrolled
CNS

Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡